Literature DB >> 7916040

Improved survival for patients with AIDS-related Kaposi's sarcoma.

S A Miles1, H Wang, R Elashoff, R T Mitsuyasu.   

Abstract

PURPOSE: We retrospectively analyzed all patients with AIDS-related Kaposi's sarcoma (AIDS-KS) seen at one large California medical center to delineate factors that may have contributed to a relative decline in survival.
METHODS: Potential prognostic factors were analyzed individually, using the Cox proportional hazards regression model, for their association with survival. After a stepwise Cox regression procedure was applied to those factors that showed a significant effect on survival, a subset of factors that best predicted survival was identified. We then quantified the effect of the year of diagnosis on survival using a univariate Cox model. Next, we combined the year of diagnosis with the subset of prognostic factors previously identified into the Cox model to examine survival after adjustment for the prognostic factors. Survival distribution was estimated by the Kaplan-Meier method, and the 95% confidence interval for the median survival was computed using the modified reflected method.
RESULTS: In 688 patients, we identified four baseline variables that best predicted survival: CD4 cell number, hematocrit, number of KS lesions, and body mass index (BMI). Adjusted for these predictive factors, there was a significant improvement in survival for patients with AIDS-KS over the last 6 years.
CONCLUSION: Contrary to prior reports, survival has increased for patients with AIDS-KS. The apparent increase in observed mortality is most likely due to a decline in the CD4 cell number at presentation.

Entities:  

Mesh:

Year:  1994        PMID: 7916040     DOI: 10.1200/JCO.1994.12.9.1910

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  1 in total

1.  Severe Kaposi Sarcoma in an Urban Public Hospital.

Authors:  Shirin Elisha Kasturia; Clifford Gunthel; Cheng Zeng; Minh Ly Nguyen
Journal:  AIDS Res Hum Retroviruses       Date:  2017-01-31       Impact factor: 2.205

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.